Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kazia Therapeutics ( (KZIA) ) has provided an announcement.
On July 31, 2025, Kazia Therapeutics Limited announced a private placement agreement with institutional investors, expected to close on August 4, 2025, to raise approximately $2 million. The proceeds will support the clinical development of its lead programs, paxalisib and EVT801, and general corporate purposes. This strategic move aims to bolster Kazia’s financial position and advance its clinical-stage assets, reflecting the company’s commitment to progressing its oncology-focused drug development efforts.
The most recent analyst rating on (KZIA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an innovative oncology-focused drug development company based in Sydney, Australia. The company is primarily engaged in developing treatments for brain cancer and advanced breast cancer, with lead programs including paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, and EVT801, a selective VEGFR3 inhibitor.
Average Trading Volume: 1,066,598
Technical Sentiment Signal: Sell
Current Market Cap: $9.37M
Learn more about KZIA stock on TipRanks’ Stock Analysis page.